0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Brief Communications |

Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy

Arthur M.F. Yee, MD, PhD; and Mark B. Pochapin, MD
[+] Article and Author Information

From Hospital for Special Surgery and New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York.


Acknowledgments: The authors thank Drs. Flavia A. Golden, Stephen A. Paget, and Lionel B. Ivashkiv for critical reading of the manuscript.

Requests for Single Reprints: Arthur M.F. Yee, MD, PhD, Hospital for Special Surgery, 535 East 70th Street, New York, NY 10021.

Current Author Addresses: Dr. Yee: Division of Rheumatic Diseases, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 East 70th Street, New York, NY 10021.

Dr. Pochapin: Division of Digestive Diseases, New York Presbyterian Hospital, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021.

Author Contributions: Conception and design: A.M.F. Yee.

Analysis and interpretation of the data: A.M.F. Yee, M.B. Pochapin.

Drafting of the article: A.M.F. Yee.

Critical revision of the article for important intellectual content: A.M.F. Yee, M.B. Pochapin.

Final approval of the article: A.M.F. Yee, M.B. Pochapin.

Provision of study materials or patients: A.M.F. Yee, M.B. Pochapin.

Administrative, technical, or logistic support: A.M.F. Yee.

Collection and assembly of data: A.M.F. Yee, M.B. Pochapin.


Ann Intern Med. 2001;135(1):27-31. doi:10.7326/0003-4819-135-1-200107030-00010
Text Size: A A A

Background: Tumor necrosis factor-α (TNF-α) may have an important role in the clinical exacerbation of sarcoidosis.

Objective: To treat sarcoidosis with infliximab, a chimeric human–murine anti–human TNF-α monoclonal antibody.

Design: Case report.

Setting: U.S. academic medical center.

Patient: A 72-year-old woman with sarcoidosis presenting with severe protein-losing enteropathy, hypoalbuminemia, and proximal myopathy who had not responded adequately to corticosteroid therapy and whose clinical course was further complicated by acute tubular necrosis and renal failure requiring long-term hemodialysis.

Intervention: Intravenous infusion of infliximab, 5 mg/kg of ideal body weight; infusion was repeated at 2 and 6 weeks.

Measurements: Clinical response of enteropathic and myopathic symptoms and serum albumin level.

Results: Enteropathic and myopathic symptoms resolved after infliximab therapy, and the serum albumin level also improved. However, the clinical course was complicated by the development of a hypercoagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuation of infliximab therapy.

Conclusions: Infliximab therapy was successful in a patient with sarcoidosis. Tumor necrosis factor-α may be an important mediator of clinical disease in sarcoidosis and could be an attractive target for therapeutic intervention. However, infliximab may cause adverse effects associated with cytokine cascade manipulation.

Figures

Grahic Jump Location
Figure.
Changes in serum albumin level.

Asterisks denote intravenous methylprednisolone pulses (1.0 g/d for 3 days). White arrows denote intravenous administration of infliximab (5 mg/kg of ideal body weight). The black arrow denotes initiation of oral thalidomide, 100 mg/d.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

A New Anti-Inflammatory Therapy (Infliximab) for Complicated Sarcoidosis

The summary below is from the full report titled “Treatment of Complicated Sarcoidosis with Infliximab Anti–Tumor Necrosis Factor-α Therapy.” It is in the 3 July 2001 issue of Annals of Internal Medicine (volume 135, pages 27-31). The authors are AMF Yee and MB Pochapin.

Read More...

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)